First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany

ALK ( ALKB:DC / OMX: ALK B ) today announced the first market launch of EURneffy ®2 mg (the trade name for  neffy ® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.With an intuitive, needle-free design, EURneffy ®can help more people confidently use adrenaline when it matters most,...

Hørsholm, 26/06/2025 (informazione.news - comunicati stampa - economia)

ALK ( ) today announced the first market launch of EURneffy 2 mg (the trade name for  neffy  in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions.

With an intuitive, needle-free design, EURneffy can help more people confidently use adrenaline when it matters most, supporting fast, reliable emergency treatment and ultimately helping improve the chances of successful outcomes and save lives. EURneffy offers a longer shelf life (30 months) and superior temperature stability compared to existing adrenaline auto-injectors (AAIs).

ALK's Senior Vice President of Commercial Operations in Europe, Flora Beiche-Scholz, said:  

The EU approval was based on the review of data from the EUR development programme involving more than 700 participants. No serious adverse events were reported in clinical studies with EUR . The extensive clinical pharmacological data of EUR 2 mg was comparable to AAIs, with the pharmacodynamics and pharmacokinetics evaluated across a range of dosing conditions. EURneffy with a 1 mg dosage for patients weighing 15-30 kg is currently undergoing an EU regulatory review process which is expected to complete in 2026.

In Europe, anaphylaxis occurs in up to eight out of every 100,000 people each year, and one in 300 people experiences it at some point in their lives. In emergency situations, uncertainty and hesitation with larger auto-injectors are apparent among those at risk.

In November 2024, ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. granting ALK exclusive global rights to commercialise neffy (including EURneffy in EU) with exception of the USA, Australia, New Zealand, Japan, and China. In May 2025, the partnership was extended to include a co-promotion agreement in the USA.

The market launch does not affect ALK’s financial guidance for 2025.  

Investor Relations : Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

: Maiken Riise Andersen, tel. +45 5054 1434

Attachment